🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. Dynepo (Epoetin delta)

    Takeda Pharmaceuticals International AG

    Anemia

    phase 3 small molecule terminated

    1 trial

  2. ERYTHROPOIETIN , Elritercept

    Takeda Pharmaceuticals International AG

    Myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  3. Elritercept

    Takeda Pharmaceuticals International AG

    Myelodysplastic Syndromes

    phase 3 small molecule active

    2 trials

  4. Elritercept

    Takeda Pharmaceuticals International AG

    Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  5. Emicizumab

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 small molecule active

    1 trial

  6. Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 108 mg solution for injection in pre-filled pen

    Takeda Pharmaceuticals International AG

    Ulcerative Colitis or Crohn’s Disease

    phase 3 small molecule active

    1 trial

  7. Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda Pharmaceuticals International AG

    Active Ulcerative Colitis or Crohn’s Disease

    phase 3 small molecule active

    1 trial

  8. Epoetin

    Takeda Pharmaceuticals International AG

    Chronic Kidney Disease

    phase 3 small molecule completed

    1 trial

  9. Escitalopram

    Takeda Pharmaceuticals International AG

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial

  10. Expanded autologous adipose-derived adult stem cells (eASCs)

    Takeda Pharmaceuticals International AG

    Complex Perianal Fistula

    phase 3 small molecule terminated

    1 trial

  11. Extended-release Guanfacine HCl (Intuniv, SPD503)

    Takeda Pharmaceuticals International AG

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  12. Extended-release Guanfacine Hydrochloride

    Takeda Pharmaceuticals International AG

    Attention-deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    3 trials

  13. FEIBA

    Takeda Pharmaceuticals International AG

    Hemophilia A or B With Inhibitors

    phase 3 mab completed

    1 trial

  14. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda Pharmaceuticals International AG

    Acute Fungal Otitis Externa

    phase 3 small molecule terminated

    1 trial

  15. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda Pharmaceuticals International AG

    Acute Otitis Externa

    phase 3 small molecule terminated

    1 trial

  16. FST201 (dexamethasone 0.1% with povidone-iodine 1%)

    Takeda Pharmaceuticals International AG

    Acute Otitis Externa

    phase 3 small molecule completed

    1 trial

  17. Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)

    Takeda Pharmaceuticals International AG

    Hemophilia A or B With Inhibitors

    phase 3 mab completed

    1 trial

  18. Fasiglifam

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    2 trials

  19. Fasiglifam (TAK-875)

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    1 trial

  20. Fasiglifam (TAK-875)

    Takeda Pharmaceuticals International AG

    Glycemic Control

    phase 3 small molecule terminated

    1 trial

  21. Fazirsiran Injection

    Takeda Pharmaceuticals International AG

    Alpha1-Antitrypsin Deficiency

    phase 3 small molecule active

    3 trials

  22. Febuxostat

    Takeda Pharmaceuticals International AG

    Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  23. Febuxostat IR

    Takeda Pharmaceuticals International AG

    Gout

    phase 3 small molecule completed

    2 trials

  24. Fibrinogen (human) + thrombin (human) (TachoSil)

    Takeda Pharmaceuticals International AG

    Surgical Resection of Superficial Renal Tumour

    phase 3 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources